title: Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis.
abstract: Overexpression of C-natriuretic peptide (CNP) in cartilage partially rescues achondroplasia in the mouse. Here, we studied the interaction of fibroblast growth factor (FGF) and CNP signaling in chondrocytes. CNP antagonized FGF2-induced growth arrest of rat chondrosarcoma (RCS) chondrocytes by inhibition of the Erk mitogen activated protein kinase pathway. This effect of CNP was protein kinase G-dependent and was mimicked by the cGMP analog pCPT-cGMP. FGF2-mediated activation of both MEK and Raf-1 but not Ras or FRS2 was abolished by CNP demonstrating that CNP blocks the Erk pathway at the level of Raf-1. CNP also counteracted the FGF2-mediated degradation of RCS extracellular matrix. CNP partially antagonized FGF2-induced expression, release and activation of several matrix-remodeling molecules including matrix metalloproteinase 2 (MMP2), MMP3, MMP9, MMP10 and MMP13. In addition, CNP compensated for FGF2-mediated matrix loss by upregulation of matrix production independent of its interference with FGF signaling. We conclude that CNP utilizes both direct and indirect ways to counteract the effects of FGF signaling in a chondrocyte environment.
authors.affiliation: Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Pavel
authors.initials: P
authors.lastname: Krejci
authors.forename: Bernard
authors.initials: B
authors.lastname: Masri
authors.forename: Vincent
authors.initials: V
authors.lastname: Fontaine
authors.forename: Pertchoui B
authors.initials: PB
authors.lastname: Mekikian
authors.forename: Maryann
authors.initials: M
authors.lastname: Weis
authors.forename: Herve
authors.initials: H
authors.lastname: Prats
authors.forename: William R
authors.initials: WR
authors.lastname: Wilcox
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019902:Chondrocytes / Q000166:cytology* / Q000378:metabolism; D002813:Chondrosarcoma / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D006152:Cyclic GMP / Q000378:metabolism; D017869:Cyclic GMP-Dependent Protein Kinases; D005109:Extracellular Matrix / Q000378:metabolism / Q000473:pathology / Q000502:physiology*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D006131:Growth Inhibitors / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D006706:Homeostasis / Q000502:physiology*; D020935:MAP Kinase Signaling System / Q000502:physiology; D020098:Natriuretic Peptide, C-Type / Q000378:metabolism / Q000502:physiology*; D010766:Phosphorylation; D019908:Proto-Oncogene Proteins c-raf / Q000378:metabolism; D051381:Rats; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D006131:Growth Inhibitors; D016222:Fibroblast Growth Factor 2; D020098:Natriuretic Peptide, C-Type; D019908:Proto-Oncogene Proteins c-raf; D017869:Cyclic GMP-Dependent Protein Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D006152:Cyclic GMP